Press Release Details

Cerus Corporation Invites You to Join a Webcast of its Second Quarter Conference Call

July, 21 2001

CONCORD, Calif., July 17 /PRNewswire/ --

In conjunction with Cerus Corporation's Second Quarter Financial Results release, you are invited to listen to its conference call that will be broadcast live over the Internet on July 24, 2001 at 4:30 p.m. EDT with Stephen Isaacs, President and CEO, Greg Schafer, CFO, and Laurence Corash, M.D., VP, Medical Affairs of Cerus Corporation (Nasdaq: CERS).

What: Cerus Corporation Second Quarter Financial Results

as well as an Update on Progress and Future Outlook

When: Tuesday, July 24, 4:30 p.m. EDT

Where:http://www.videonewswire.com/event.asp?id=146

How: Live over the Internet -- Simply log on to the web

at the address above

Contact: Lisa Luttinger of Cerus Corporation, +1-925-288-6036

Cerus Corporation is building on its leading position in the biopharmaceutical industry by developing medical systems and therapeutics to provide safer and more effective options to patients. The company is developing products based on its proprietary Helinx(TM) technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. These INTERCEPT Blood Systems, based on the company's Helinx technology, are designed to inactivate viruses, bacteria, other pathogens and white blood cells. In collaboration with its partner, Baxter Healthcare Corporation, the company has completed Phase III trials for the INTERCEPT Platelet System and is conducting Phase III trials for the INTERCEPT Plasma System. Also in collaboration with Baxter, the company is preparing to begin a Phase III trial for the INTERCEPT Red Blood Cell System. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.

NOTE: Helinx is a trademark of Cerus Corporation. INTERCEPT Blood System, INTERCEPT Platelet System, INTERCEPT Plasma System and INTERCEPT Red Blood Cell System are trademarks of Baxter International, Inc. (NYSE: BAX)

If you are unable to participate during the live webcast, the call will be archived for 72 hours on the Website www.cerus.com.

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from www.real.com/products/player/index.html, and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to webmaster@vdat.com.)

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X31233348

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600